Gilead Pharmasset LLC

Anadys Pharmaceuticals, Inc.

Effector Therapeutics, Inc.

Gilead Sciences, Inc.

Hoffmann-La Roche Inc.

Sony Corporation

Qualcomm Incorporated

Sony Electronics Inc

Chinh Viet Tran

John O Link

James G Taylor

Jeromy J Cottell

Zheng-Yu Yang

Darryl Kato

Sheila M Zipfel

Teresa Alejandra Trejo Martin

Ashley Anne Katana

Frank Ruebsam

Douglas Eric Murphy

Peter Scott Dragovich

Elizabeth M Bacon

Evan S Krygowski

Stephen Evan Webber

David J Kucera

Siegfried Heinz Reich

Justin T Ernst

Alan X Xiang

Paul A Sprengeler

Yuefen Zhou

Jeff A Zablocki

Liansheng Li

Hyung-Jung Pyun

Dustin S Siegel

Barton W Phillips

Eda Y Canales

Tetsuya Kobayashi

Randall W Vivian

Adam James Schrier

Michael Sangi

Garrick Kenneth Packard

Ruben Martinez

Kapil Kumar Karki

Theo Michels

Christian Nilewski

Kyla Bjornson

Zhongxiang Sun

Lijian Chen

Martin Tran

Fritz Blatter

Robert Francis Kester

Martin Viertelhaus

Steven Joseph Berthel

Dionisios Vourloumis

Thomas Jay Prins

Mike Shaghafi

Li Feng Zhang

Bohuslav Rychlik

Ramakanth Sarabu

Chi-ping Nee

Joseph C Chan

Madan Krishnappa

Samuel Sperry

David Ellis

Peggy A Thompson

Kaveri Urkalan

Kyla Ramey

Alan Grubbs

Douglas Murphy

Alan Young

Takasuke Mukaiyama

William Bainbridge

Jeff Zablocki

Alan Xin Xiang

Theodore Michels

James Taylor

Jeromy Cottell

David John Kucera

Douglas E Murphy

Martin T Tran

Dustin Siegel

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, Y, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4A-inhibiting compounds and methods related thereto

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, X, X, X, X, X, Q, L, L, Y, R, R, R, R, R, R, R, Rand rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4E-inhibiting compounds and methods

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Antiviral compounds

Compounds of Formula I are disclosed  As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Inhibitors of hepatitis C virus

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A, A, A, A, A, W, Y, R, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rand subscript 'n' are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2

eIF4A-inhibiting compounds and methods related thereto

Various embodiments of methods and systems for bit flip identification for debugging and/or power management in a system on a chip ('SoC') are disclosed. Exemplary embodiments seek to identify bit flip occurrences near in time to the occurrences by checking parity values of data blocks as the data blocks are written into a memory component. In this way, bit flips occurring in association with a write transaction may be differentiated from bit flips occurring in association with a read transaction. The distinction may be useful, when taken in conjunction with various parameter levels identified at the time of a bit flip recognition, to debug a memory component or, when in a runtime environment, adjust thermal and power policies that may be contributing to bit flip occurrences.

Systems and methods of memory bit flip identification for debugging and power management

Growing community of inventors

San Diego, CA, United States of America

Chinh Viet Tran